Literature DB >> 8025349

The importance of blood cell-vessel wall interactions in tumour metastasis.

A Poggi1, M Stella, M B Donati.   

Abstract

Tumour cell dissemination is a complex process, depending on the ability of malignant cells to escape from the primary tumour and penetrate and flow through the bloodstream. Circulating tumour cells can adhere to the vessel wall, dissolve the basal lamina and extravasate, giving origin to metastases. Interactions between tumour cells, blood platelets and leukocytes favour tumour cell adhesion to the vessel wall, migration in extravascular spaces and growth in secondary sites. The biochemical and molecular mechanisms regulating tumour cell adhesion to the vessel wall and intercellular contacts have been studied extensively in recent years. Moreover, it has been shown that either tumour cells or blood cells release growth factors and inflammatory proteins, such as cytokines and chemokines, that may be involved in tumour cell migration and proliferation. Finally, tumour cells and cells of the surrounding tissue possess procoagulant and fibrinolytic properties that may be important in modulating the extracellular matrix around the tumour, to allow tumour cell invasion and progression. We have described the cell types (i.e. blood platelets, leukocytes, endothelial cells), the matrix components (i.e. fibronectin, thrombospondin and laminin) and the growth factors/cytokines (i.e. platelet-derived growth factor, transforming growth factor beta, tumour necrosis factor) involved in these processes. In particular, we have described cell-cell and cell-matrix interactions, cell migration and release of growth factors, cytokines, chemotactic peptides and proteolytic enzymes. This survey has also considered a few innovative approaches for the prevention and cure of cancer and metastasis that are based on these new concepts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8025349     DOI: 10.1016/s0950-3536(05)80196-9

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  9 in total

1.  Prognostic value of thrombocytosis in patients undergoing surgery for colorectal cancer with synchronous liver metastases.

Authors:  C Pedrazzani; G Turri; G Mantovani; C Conti; R Ziello; S Conci; T Campagnaro; A Ruzzenente; A Guglielmi
Journal:  Clin Transl Oncol       Date:  2019-04-02       Impact factor: 3.405

Review 2.  Pathogenesis of thrombosis in patients with malignancy.

Authors:  A Falanga; M B Donati
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

3.  Kaposi's sarcoma in an HIV-negative CLL patient as the cause of thrombocytopenia.

Authors:  P W Wijermans; K van Groningen; E A van Royen; J A Bruijn
Journal:  Ann Hematol       Date:  1994-06       Impact factor: 3.673

Review 4.  The prothrombotic activity of cancer cells in the circulation.

Authors:  Annachiara Mitrugno; Garth W Tormoen; Peter Kuhn; Owen J T McCarty
Journal:  Blood Rev       Date:  2015-07-14       Impact factor: 8.250

5.  Heparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells.

Authors:  Y Tanaka; K Kimata; A Wake; S Mine; I Morimoto; N Yamakawa; H Habuchi; S Ashikari; H Yamamoto; K Sakurai; K Yoshida; S Suzuki; S Eto
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

6.  Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma.

Authors:  Eugene J Vaios; Sebastian F Winter; Alona Muzikansky; Brian V Nahed; Jorg Dietrich
Journal:  Neurooncol Adv       Date:  2020-03-11

7.  ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.

Authors:  R Grützmann; J Lüttges; B Sipos; O Ammerpohl; F Dobrowolski; I Alldinger; S Kersting; D Ockert; R Koch; H Kalthoff; H K Schackert; H D Saeger; G Klöppel; C Pilarsky
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

8.  A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma.

Authors:  Keeratikarn Boonyawan; Kenneth R Hess; Jie Yang; Lihong Long; Qianghu Wang; Ravesanker Ezhilarasan; Alessandra Auia; Kristin D Alfaro-Munoz; John F de Groot; Krishna P Bhat; Erik P Sulman
Journal:  Oncotarget       Date:  2017-10-12

9.  The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation.

Authors:  Jan Moritz Ponert; Svenja Schwarz; Reza Haschemi; Jens Müller; Bernd Pötzsch; Gerd Bendas; Martin Schlesinger
Journal:  PLoS One       Date:  2018-01-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.